My father's journey, aged 76, started in July 2022, when he was diagnosed with de novo metastatic prostate cancer, with multiple bone mets and a PSA reading of 839 ng/mL, gleason score 8. At that time, his right hip and lower back were in excruciating pain, his mobility was impaired and his appetite was significantly reduced.
Soon after, he was put on androgen deprivation therapy, including the quarterly injections we all know and bicalutamide tablets (150 mg initially and later on 50 mg, daily). Xgeva has also been administered, for his bone mets, on a monthly basis.
He was doing well, as his PSA level followed a declining trajectory :188 in August, 40 in September, 20 in October, 10 in November and 8,5 in December 2022. But, in January 2023, it rose to 15. In February, he had CT scan, showing no changes and PET scan, showing two new small areas (in a rib and a vertebra) and amelioration of the already known mets. And, even though his testosterone was at castrate level, his PSA reading was 50 ng/mL, in February, so he switched from bicalutamide to enzalutamide. But after 20 days, that is today, his PSA has skyrocketed, reaching almost 150 ng/mL.
Good news that he eats well, has no pain and walks.
But I'm very concerned and that is the least I can utter...
Edited by member 08 Apr 2023 at 16:15
| Reason: Not specified